Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

616

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Stomach Cancer
Interventions
DRUG

nab paclitaxel

nab paclitaxel (120mg/m2;iv;d1,8)

DRUG

Tegafur

S-1 (\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg;po;d1-14 bid)

DRUG

Oxaliplatin

Oxaliplatin(130mg/m2 , iv, d1)

DRUG

Capecitabine

Capetabine(1000 mg/m2 po, d1-14 bid )

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences, Hangzhou

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Zhejiang Cancer Hospital

OTHER

NCT04135781 - Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | Biotech Hunter | Biotech Hunter